|Bid||1.25 x 4000|
|Ask||2.49 x 2900|
|Day's Range||2.2200 - 2.4850|
|52 Week Range||1.8800 - 5.8600|
|Beta (3Y Monthly)||3.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.28|
NEW YORK, Dec. 03, 2018 -- Kadmon Holdings, Inc. (NYSE: KDMN) today announced updated data from its ongoing Phase 2 clinical trial of KD025, its selective oral inhibitor of.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, Nov. 09, 2018 -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the third quarter of 2018..
Kadmon Holdings, Inc. (KDMN) today announced that the first patient has been dosed in a pivotal clinical trial of KD025 in chronic graft-versus-host disease (cGVHD). The study will evaluate the efficacy and safety of KD025, Kadmon’s ROCK2 inhibitor, in adults with cGVHD who have received at least two prior lines of systemic therapy. ROCKstar (KD025-213) is a Phase 2 open-label trial in which patients will be randomized to receive KD025 200 mg QD or KD025 200 mg BID, enrolling 63 patients per arm.
Kadmon Holdings, Inc. (KDMN) today announced that Konstantin Poukalov has notified the company of his intent to step down as Executive Vice President, Chief Financial Officer (CFO) and Principal Accounting Officer (PAO), effective immediately. Kyle Carver, the Company’s Controller, has been appointed PAO and will report directly to the Company’s President and Chief Executive Officer (CEO) while the Company searches for a new CFO. “We appreciate Konstantin’s commitment to Kadmon since he joined us in 2012, and he leaves the Company in a very strong cash position,” said Harlan W. Waksal, M.D., President and CEO at Kadmon.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Kadmon Holdings, Inc. (KDMN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KD025, the company’s ROCK2 inhibitor, for the treatment of patients with chronic graft-versus-host disease (cGVHD) after failure of two or more lines of systemic therapy. The FDA selectively grants Breakthrough Therapy Designation to expedite the development and review of a drug that is intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies.
Exact Sciences (NASDAQ:EXAS) shares have bolted above both their 50-day and 200-day moving averages, rising nearly 30% in mid-day trading on Wednesday to return to the upper end of a three-month trading range. The company will next report results on Oct. 31, after the bell. When the company last reported on Aug. 1, a loss of 30-cents-per-share beat estimates by 3 cents on a 79% rise in revenues on a year-over-year basis.
Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the second quarter of 2018.
Kadmon Holdings, Inc. today announced updated efficacy and safety results from an ongoing Phase 2 clinical trial evaluating KD025 in patients with steroid-dependent or refractory chronic graft-versus-host disease .
Kadmon Holdings, Inc. (KDMN) today announced the closing of its previously announced offerings of common stock for gross proceeds of approximately $113.2 million, which includes the full exercise of the underwriters’ option to purchase additional shares. Proceeds from the offerings will be used for preclinical and clinical development of Kadmon’s lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes. “This financing is a testament to the significant potential of KD025 in cGVHD and provides the resources that we believe will allow us to pursue regulatory approval in this indication,” said Harlan W. Waksal, M.D., President and CEO at Kadmon.
Kadmon Holdings (KDMN) is an integrated biopharmaceutical company. On June 11, Kadmon Holdings announced the pricing of its common stock offerings. Following the news, the stock price increased ~9.8% and closed at $3.68 on June 12.
Kadmon Holdings, Inc. (KDMN) today announced the pricing of an offering of an aggregate of 30,303,030 shares of its common stock at an offering price of $3.30 per share in an underwritten offering (the “Underwritten Offering”) and a registered direct offering to certain institutional investors (the “Direct Offering” and, together with the Underwritten Offering, the “Offerings”). The gross proceeds to Kadmon from the Offerings, before deducting underwriting discounts and commissions and other expenses of the Offerings, are expected to be approximately $100.0 million. Kadmon has granted the underwriters in the Underwritten Offering a 30-day option to purchase up to an additional 4,000,000 shares of Kadmon’s common stock on the same terms and conditions.
Kadmon Holdings, Inc. (KDMN) today announced its intention to offer and sell shares of its common stock in a public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC is acting as the sole book-running manager for the offering.
Kadmon Holdings, Inc. (KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present an overview of the Company and its clinical programs at the Jefferies 2018 Global Healthcare Conference in New York on Tuesday, June 5, 2018 at 10:00 a.m. ET. Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. This press release contains forward-looking statements.